The stock of Mettrum Health Corp (CVE:MT) gapped up by $0.02 today and has $9.99 target or 126.00% above today’s $4.42 share price. The 6 months technical chart setup indicates low risk for the $207.47M company. The gap was reported on Nov, 10 by Barchart.com. If the $9.99 price target is reached, the company will be worth $261.41 million more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 595,203 shares traded hands or 14.69% up from the average. Mettrum Health Corp (CVE:MT) has risen 6.00% since October 11, 2016 and is uptrending. It has outperformed by 0.35% the S&P500.
More important recent Mettrum Health Corp (CVE:MT) news were published by: Investingnews.com which released: “Mettrum Health” on June 06, 2016, also Reuters.com published article titled: “BRIEF-Mettrum Health Corp says all licenses at Bowmanville facilities rene…”, Reuters.com published: “BRIEF-Mettrum Health Q1 loss per share $0.03” on November 16, 2014. More interesting news about Mettrum Health Corp (CVE:MT) was released by: Marketwired.com and their article: “Mettrum Health Corp. Announces Full Exercise of Over-Allotment Option” with publication date: September 07, 2016.
Mettrum Health Corp. is a producer of medical cannabis. The company has a market cap of $207.47 million. The Firm is also a licensed producer and distributer of industrial cannabis (hemp) products, including Mettrum’s functional food line, Mettrum Originals. It currently has negative earnings. It has a production capacity of over 12,000 kilograms of medical cannabis per year.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.